Figg j (16 risultati)

Perfeziona la tua ricerca

  • Libri (16)

a

Fascia di prezzo personalizzata (EUR)

a

  • Lingua: Francese

    Editore: USBORNE, 2006

    0746075758 / 9780746075753

    • Brossura

    Da: Ammareal, Morangis, FranciaAmmareal

    Venditore con 5 stelle
    Contatta il venditore

    Condizione: Usato - Quasi ottimo

    Affare

    Prezzo corrente: EUR 3,15

    EUR 16,50 spedizione 
    Spedito da Francia a U.S.A.

    Quantità: 1 disponibili

    Softcover. Condizione: Bon. Ancien livre de bibliothèque. Edition 2006. Ammareal reverse jusqu'à 15% du prix net de cet article à des organisations caritatives. ENGLISH DESCRIPTION Book Condition: Used, Good. Former library book. Edition 2006. Ammareal gives back up to 15% of this item's net price to charity organizations. Katrina Fearn; Non Figg; Katie Lovell; Jan McCafferty; Antonia Miller (illustratore).

  • Lingua: Inglese

    Editore: Springer, 2010

    1603278311 / 9781603278317

    • Rilegato

    Da: Basi6 International, Irving, TX, U.S.A.Basi6 International

    Venditore con 5 stelle
    Contatta il venditore

    Condizione: Nuovo

    EUR 85,73

     Spedizione gratuita 
    Spedito in U.S.A.

    Quantità: 1 disponibili

    Condizione: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service.

  • Lingua: Inglese

    Editore: Garland Publishing, 2000

    0815320035 / 9780815320036

    • Rilegato

    Da: Anybook.com, Lincoln, Regno UnitoAnybook.com

    Venditore con 5 stelle
    Contatta il venditore

    Condizione: Usato - Mediocre

    EUR 72,24

    EUR 20,54 spedizione 
    Spedito da Regno Unito a U.S.A.

    Quantità: 1 disponibili

    Condizione: Poor. This is an ex-library book and may have the usual library/used-book markings inside.This book has hardback covers. In poor condition, suitable as a reading copy. No dust jacket. Please note the Image in this listing is a stock photo and may not match the covers of the actual item,2000grams, ISBN:9780815320036.

  • Lingua: Inglese

    Editore: HMSO, London, 1985

    0114119120 / 9780114119126

    • Brossura
    • Prima edizione

    Da: Webbooks, Wigtown, Wigtown, Regno UnitoWebbooks, Wigtown

    Venditore con 5 stelle
    Contatta il venditore

    Membro dell’associazione: PBFA

    Condizione: Usato - Buono

    EUR 57,63

    EUR 34,97 spedizione 
    Spedito da Regno Unito a U.S.A.

    Quantità: 1 disponibili

    Soft Cover. Condizione: Good. No Jacket. First Edition. From an academic library with the usual stamps etc. Covers have been laminated. B00005384.

  • Lingua: Inglese

    Editore: Royal Society of Chemistry, 1996

    085404731X / 9780854047314

    • Rilegato

    Da: Romtrade Corp., STERLING HEIGHTS, MI, U.S.A.Romtrade Corp.

    Venditore con 5 stelle
    Contatta il venditore

    Condizione: Nuovo

    EUR 140,88

     Spedizione gratuita 
    Spedito in U.S.A.

    Quantità: 1 disponibili

    Condizione: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide.

  • Lingua: Inglese

    Editore: Springer New York, 2010

    1603278311 / 9781603278317

    • Rilegato

    Da: Buchpark, Trebbin, GermaniaBuchpark

    Venditore con 5 stelle
    Contatta il venditore

    Condizione: Usato - Ottimo

    EUR 52,18

    EUR 105,00 spedizione 
    Spedito da Germania a U.S.A.

    Quantità: 1 disponibili

    Condizione: Sehr gut. Zustand: Sehr gut | Seiten: 448 | Sprache: Englisch | Produktart: Bücher | Prostate cancer is the most common noncutaneous prostate cancer. Research has revealed several distinct malignancy and the second leading cause of cancer mechanisms of castration-resistant disease that may deaths among men in the United States. It is a critical converge in patients with disease progression on public health problem and remains incurable in the ADT. Many approaches are currently being evaluated metastatic setting with mortality that usually occurs as to improve the treatment of this condition and these a result of castration-resistant disease. fndings have identifed several potential targets for Since Huggins and Hodges¿ report of the dra- therapeutic intervention. These include drugs that are matic clinical effects of suppressing serum testos- more active or less toxic chemotherapy agents; drugs terone levels in men with advanced prostate cancer that induce androgen deprivation; drugs that target in 1941, hormone therapy (also called androgen the androgen receptor and/or androgen synthesis; deprivation therapy [ADT]) has become widely drugs that target specifc pathways, including ang- accepted as the mainstay of therapy for the treat- genesis and tyrosine kinase inhibitors, endothelin ment of advanced prostate cancer. ADT combined antagonists and matrix metalloproteinase inhibitors; with radiation therapy is a standard of care in the and immunologic approaches. Many of these agents treatment of men with locally advanced prostate seem promising and the rationale and effcacy of cancer on the basis of evidence that shows improved these emerging therapies remain to be validated in survival. The role of ADT in the management of future clinical trials.

  • Lingua: Inglese

    Editore: Royal Society of Chemistry, 1996

    085404731X / 9780854047314

    • Rilegato

    Da: Mispah books, Redhill, SURRE, Regno UnitoMispah books

    Venditore con 4 stelle
    Contatta il venditore

    Condizione: Usato - Come nuovo

    EUR 247,32

    EUR 29,14 spedizione 
    Spedito da Regno Unito a U.S.A.

    Quantità: 1 disponibili

    Hardcover. Condizione: Like New. LIKE NEW. SHIPS FROM MULTIPLE LOCATIONS. book.

  • Lingua: Inglese

    Editore: Humana Press, 2010

    1603278311 / 9781603278317

    • Rilegato

    Da: Books Puddle, Woodside, NY, U.S.A.Books Puddle

    Venditore con 4 stelle
    Contatta il venditore

    Condizione: Nuovo

    EUR 291,00

    EUR 3,49 spedizione 
    Spedito in U.S.A.

    Quantità: 4 disponibili

    Condizione: New. pp. 698 1st Edition.

  • Lingua: Inglese

    Editore: Springer, 2010

    1603278311 / 9781603278317

    • Rilegato

    Da: Mispah books, Redhill, SURRE, Regno UnitoMispah books

    Venditore con 4 stelle
    Contatta il venditore

    Condizione: Usato - Come nuovo

    EUR 345,76

    EUR 29,14 spedizione 
    Spedito da Regno Unito a U.S.A.

    Quantità: 1 disponibili

    Hardcover. Condizione: Like New. LIKE NEW. SHIPS FROM MULTIPLE LOCATIONS. book.

  • Lingua: Inglese

    Editore: Springer, 2010

    1603278311 / 9781603278317

    • Rilegato
    • Print on Demand

    Da: Brook Bookstore On Demand, Napoli, NA, ItaliaBrook Bookstore On Demand

    Venditore con 5 stelle
    Contatta il venditore

    Condizione: Nuovo

    EUR 166,29

    EUR 11,00 spedizione 
    Spedito da Italia a U.S.A.

    Quantità: Più di 20 disponibili

    Condizione: new. Questo è un articolo print on demand.

  • Lingua: Inglese

    Editore: Springer New York, 2010

    1603278311 / 9781603278317

    • Rilegato
    • Print on Demand

    Da: moluna, Greven, Germaniamoluna

    Venditore con 5 stelle
    Contatta il venditore

    Condizione: Nuovo

    EUR 175,51

    EUR 48,99 spedizione 
    Spedito da Germania a U.S.A.

    Quantità: Più di 20 disponibili

    Condizione: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Provides a comprehensive guide to the spectrum of emerging pharmacologic agentsCovers both standard of care and investigational therapeuticsWritten by recognized international authorities in the fieldWell suited .

  • Lingua: Inglese

    Editore: Springer New York, Springer US Sep 2010, 2010

    1603278311 / 9781603278317

    • Rilegato
    • Print on Demand

    Da: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, GermaniaBuchWeltWeit Ludwig Meier e.K.

    Venditore con 5 stelle
    Contatta il venditore

    Condizione: Nuovo

    EUR 213,99

    EUR 23,00 spedizione 
    Spedito da Germania a U.S.A.

    Quantità: 2 disponibili

    Buch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Prostate cancer is the most common noncutaneous prostate cancer. Research has revealed several distinct malignancy and the second leading cause of cancer mechanisms of castration-resistant disease that may deaths among men in the United States. It is a critical converge in patients with disease progression on public health problem and remains incurable in the ADT. Many approaches are currently being evaluated metastatic setting with mortality that usually occurs as to improve the treatment of this condition and these a result of castration-resistant disease. fndings have identifed several potential targets for Since Huggins and Hodges' report of the dra- therapeutic intervention. These include drugs that are matic clinical effects of suppressing serum testos- more active or less toxic chemotherapy agents; drugs terone levels in men with advanced prostate cancer that induce androgen deprivation; drugs that target in 1941, hormone therapy (also called androgen the androgen receptor and/or androgen synthesis; deprivation therapy [ADT]) has become widely drugs that target specifc pathways, including ang- accepted as the mainstay of therapy for the treat- genesis and tyrosine kinase inhibitors, endothelin ment of advanced prostate cancer. ADT combined antagonists and matrix metalloproteinase inhibitors; with radiation therapy is a standard of care in the and immunologic approaches. Many of these agents treatment of men with locally advanced prostate seem promising and the rationale and effcacy of cancer on the basis of evidence that shows improved these emerging therapies remain to be validated in survival. The role of ADT in the management of future clinical trials. 448 pp. Englisch.

  • Lingua: Inglese

    Editore: Springer New York, Copernicus Sep 2010, 2010

    1603278311 / 9781603278317

    • Rilegato
    • Print on Demand

    Da: buchversandmimpf2000, Emtmannsberg, BAYE, Germaniabuchversandmimpf2000

    Venditore con 5 stelle
    Contatta il venditore

    Condizione: Nuovo

    EUR 213,99

    EUR 60,00 spedizione 
    Spedito da Germania a U.S.A.

    Quantità: 1 disponibili

    Buch. Condizione: Neu. This item is printed on demand - Print on Demand Titel. Neuware -Prostate cancer is the most common noncutaneous prostate cancer. Research has revealed several distinct malignancy and the second leading cause of cancer mechanisms of castration-resistant disease that may deaths among men in the United States. It is a critical converge in patients with disease progression on public health problem and remains incurable in the ADT. Many approaches are currently being evaluated metastatic setting with mortality that usually occurs as to improve the treatment of this condition and these a result of castration-resistant disease. fndings have identifed several potential targets for Since Huggins and Hodges¿ report of the dra- therapeutic intervention. These include drugs that are matic clinical effects of suppressing serum testos- more active or less toxic chemotherapy agents; drugs terone levels in men with advanced prostate cancer that induce androgen deprivation; drugs that target in 1941, hormone therapy (also called androgen the androgen receptor and/or androgen synthesis; deprivation therapy [ADT]) has become widely drugs that target specifc pathways, including ang- accepted as the mainstay of therapy for the treat- genesis and tyrosine kinase inhibitors, endothelin ment of advanced prostate cancer. ADT combined antagonists and matrix metalloproteinase inhibitors; with radiation therapy is a standard of care in the and immunologic approaches. Many of these agents treatment of men with locally advanced prostate seem promising and the rationale and effcacy of cancer on the basis of evidence that shows improved these emerging therapies remain to be validated in survival. The role of ADT in the management of future clinical trials.Springer-Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 448 pp. Englisch.

  • Lingua: Inglese

    Editore: Humana Press, 2010

    1603278311 / 9781603278317

    • Rilegato
    • Print on Demand

    Da: Majestic Books, Hounslow, Regno UnitoMajestic Books

    Venditore con 4 stelle
    Contatta il venditore

    Condizione: Nuovo

    EUR 305,02

    EUR 7,58 spedizione 
    Spedito da Regno Unito a U.S.A.

    Quantità: 4 disponibili

    Condizione: New. Print on Demand pp. 698.

  • Lingua: Inglese

    Editore: Humana Press, 2010

    1603278311 / 9781603278317

    • Rilegato
    • Print on Demand

    Da: Biblios, frankfurt am main, HESSE, GermaniaBiblios

    Venditore con 4 stelle
    Contatta il venditore

    Condizione: Nuovo

    EUR 308,75

    EUR 9,95 spedizione 
    Spedito da Germania a U.S.A.

    Quantità: 4 disponibili

    Condizione: New. PRINT ON DEMAND pp. 698.

  • Lingua: Inglese

    Editore: Humana, 2010

    1603278311 / 9781603278317

    • Rilegato
    • Print on Demand

    Da: AHA-BUCH GmbH, Einbeck, GermaniaAHA-BUCH GmbH

    Venditore con 5 stelle
    Contatta il venditore

    Condizione: Nuovo

    EUR 299,66

    EUR 43,03 spedizione 
    Spedito da Germania a U.S.A.

    Quantità: 1 disponibili

    Buch. Condizione: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Prostate cancer is the most common noncutaneous prostate cancer. Research has revealed several distinct malignancy and the second leading cause of cancer mechanisms of castration-resistant disease that may deaths among men in the United States. It is a critical converge in patients with disease progression on public health problem and remains incurable in the ADT. Many approaches are currently being evaluated metastatic setting with mortality that usually occurs as to improve the treatment of this condition and these a result of castration-resistant disease. fndings have identifed several potential targets for Since Huggins and Hodges' report of the dra- therapeutic intervention. These include drugs that are matic clinical effects of suppressing serum testos- more active or less toxic chemotherapy agents; drugs terone levels in men with advanced prostate cancer that induce androgen deprivation; drugs that target in 1941, hormone therapy (also called androgen the androgen receptor and/or androgen synthesis; deprivation therapy [ADT]) has become widely drugs that target specifc pathways, including ang- accepted as the mainstay of therapy for the treat- genesis and tyrosine kinase inhibitors, endothelin ment of advanced prostate cancer. ADT combined antagonists and matrix metalloproteinase inhibitors; with radiation therapy is a standard of care in the and immunologic approaches. Many of these agents treatment of men with locally advanced prostate seem promising and the rationale and effcacy of cancer on the basis of evidence that shows improved these emerging therapies remain to be validated in survival. The role of ADT in the management of future clinical trials.